Deferasirox (ICL670)

DRUG3 trials

Sponsors

Novartis Pharmaceuticals

Conditions

Chronic AnemiaHemolytic AnemiaHereditary HemochromatosisIron OverloadSickle Cell DiseaseTransfusional Hemosiderosis

Phase 1

Safety and Efficacy of Deferasirox (ICL670) in Patients With Iron Overload Resulting From Hereditary Hemochromatosis

CompletedNCT00395629

Novartis PharmaceuticalsHereditary Hemochromatosis, Iron Overload

Start: 2006-08-31End: 2009-03-31Updated: 2011-05-30

Phase 2

Study of Deferasirox Relative to Subcutaneous Deferoxamine in Sickle Cell Disease Patients

CompletedNCT00110617

Novartis PharmaceuticalsHemolytic Anemia, Iron Overload, Sickle Cell Disease

Start: 2005-05-31End: 2008-04-30Updated: 2011-05-26

Efficacy and Safety of Deferasirox in Patients With Chronic Anemia and Transfusional Hemosiderosis

CompletedNCT00631163

Novartis PharmaceuticalsChronic Anemia, Transfusional Hemosiderosis

Start: 2007-10-31End: 2012-02-29Updated: 2021-06-29